EU Pharma Denies Skirting Rules On Pediatric Cancer Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The European pharmaceutical industry has refuted claims that manufacturers are exploiting a loophole in EU legislation to avoid running non-lucrative trials for pediatric oncology drugs.
You may also be interested in...
European Notebook Notes Arrival Of CHMP Minutes And Biosimilar MAbs
CHMP has released for the first time the minutes of its meeting, and EMA has set up a new pharmacovigilance cluster with the FDA. A biosimilar infliximab product from Hospira and Alvogen has become the first biosimilar monoclonal antibody launched in Europe.
CHMP Clears Pierre Fabre’s Hemangiol For Children, Under Rarely Used Pediatric Pathway
Europe’s top scientific advisory panel also gave positive recommendations to BioMarin’s orphan drug Vimizim for use in mucopolysaccharidosis type IVA, and the compassionate use of a fixed combination of two of Gilead Science’s antivirals in hepatitis C, sofosbuvir and ledipasvir, after its meeting Feb. 17-20.
EMA Approves Three Oncology Drugs, Rejects One
Cancer drugs had a triumphant day at the European Medicines Agency on July 20, led by Pfizer’s Xalkori, with only one (Celgene’s Istodax) failing to make the grade.